BTG grabs back US CroFab and DigiFab rights from Nycomed

 
• By Simon Varcoe

BTG is to regain ahead of schedule the full US marketing rights to the antivenom CroFab (crotalidae polyvalent immune fab (ovine)) and the overdose product DigiFab (digoxin immune fab (ovine)) from Nycomed.

More from Focus On Asia

More from Scrip